ZIOPHARM Oncology is a clinical-stage biopharmaceutical company that develops and commercializes a range of immuno-oncology therapies for the treatment of cancer patients. Using the Sleeping Beauty platform, the company non-virally genetically engineers immune cells, T-cell receptor, and T-cell therapies. The company also has multiple license and research agreements with other organizations, including PGEN Therapeutics Inc. and The University of Texas MD Anderson Cancer Center.